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Abstract
Background: The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients’ average 5 year
survival rate from 20% to 70% in the past 30 years. However, for patients who progress after chemotherapy, its effectiveness
diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy.
Methodology/Principal Findings: In order to overcome both the dose-limiting side effects of conventional
chemotherapeutic agents and the therapeutic failure resulting from MDR, we designed and evaluated a novel drug
delivery system for MDR1 siRNA delivery. Novel biocompatible, lipid-modified dextran-based polymeric nanoparticles were
used as the platform for MDR1 siRNA delivery; and the efficacy of combination therapy with this system was evaluated. In
this study, multi-drug resistant osteosarcoma cell lines (KHOSR2 and U-2OSR2) were treated with the MDR1 siRNA
nanocarriers and MDR1 protein (P-gp) expression, drug retention, and immunofluoresence were analyzed. Combination
therapy of the MDR1 siRNA loaded nanocarriers with increasing concentrations of doxorubicin was also analyzed. We
observed that MDR1 siRNA loaded dextran nanoparticles efficiently suppresses P-gp expression in the drug resistant
osteosarcoma cell lines. The results also demonstrated that this approach may be capable of reversing drug resistance by
increasing the amount of drug accumulation in MDR cell lines.
Conclusions/Significance: Lipid-modified dextran-based polymeric nanoparticles are a promising platform for siRNA
delivery. Nanocarriers loaded with MDR1 siRNA are a potential treatment strategy for reversing MDR in osteosarcoma.
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Introduction
Drug resistance to chemotherapeutic agents is one of the major
obstacles in the treatment of human cancers. Cancer cells employ
a host of different mechanisms to become resistant to one or more
chemotherapeutic agents. One of the major causes of multidrug
resistance (MDR) is the overexpression of membrane bound drug
transporter proteins, such as P-glycoprotein (P-gp, ABCB1),
multidrug resistance-associated proteins (MRP1, ABCC1 and
MRP2, ABCC2), and breast cancer resistance protein (BCRP,
ABCG2) [1].
Osteosarcoma accounts for approximately 60% of primary
malignant bone tumors diagnosed in the first two decades of life
[2]. The cure rate for patients with localized osteosarcoma ranges
from 15% to 20% with surgery alone, but improves dramatically
to approximately 70% when combined with chemotherapy [3].
Unfortunately, the efficacy of chemotherapy is hampered by the
eventual development of MDR. It is estimated that less than 30%
of patients with recurrent disease will be cured [3,4,5].
The development and discovery of agents that reverse MDR with
high efficiency and low toxicity is the focus of extensive research
[6,7,8,9]. Unfortunately, these compounds are often nonspecific and
have low efficiency and/or high toxicity; as such, phase 3 clinical trials
of these agents are largely disappointing [6,7,10,11,12,13]. Conse-
quently, it is imperative to develop alternative, less toxic and more
efficient strategies to overcome MDR.
One of the innovative approaches to addressing MDR is to
inhibit MDR1 mRNA expression by RNA interference (RNAi).
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10764
RNAi is a technique that mimics and exploits endogenous
silencing mechanisms resulting in post-transcriptional gene
silencing of double-stranded RNA inside cells. The double-
stranded 21 to 23 nucleotide noncoding small interfering RNA
(siRNA) can knockdown expression of genes in a highly efficient
and sequence specific manner. The efficiency of RNAi and its
limited side effects have made this technique an attractive
alternative to the use of antisense oligonucleotides and ribozymes
for therapies based on the inhibition of target genes [14].
Previously, we have demonstrated that both synthetic-based and
plasmid-based siRNA can significantly block MDR1 expression in
drug resistant cell lines [15]. Although the RNAi technology is an
excellent candidate for cancer therapy, several challenges need to
be addressed for clinical application. First, the poor membrane
permeability of siRNA limits cellular uptake. Secondly, most of the
reagents for delivery of siRNA such as LipofectamineTM are toxic.
Third, siRNA is unstable and rapidly degraded by nucleases.
Further use of siRNA as therapeutic agents will rely mostly on the
development of more efficient delivery systems.
Nanotechnology offers solutions to overcome the adversity of
siRNA delivery. Several varieties of nanoparticles are available
including polymeric nanoparticles, dendrimers, inorganic/metal
nanoparticles, quantum dots, liposomes, and micelles [16]. The
versatility of polymeric nanocarriers offers a significant advantage
over other nano-carrier platforms; polymer matrices can be
selected according to utility which allows for the customization of
nanoparticle properties. Additional advantages of polymeric
nanocarriers include ease in surface modification, greater
encapsulation efficiency of the payload, payload protection, large
surface area-to-volume ratio, and the ability to modify the rate of
polymer erosion for temporal control over the release of
nucleotides [17]. Among the natural polysaccharides, dextran
based nanoparticles have been used to deliver chemotherapeutic
drugs which resulted in enhancement of drug accumulation and
increased apoptosis in cancer cells [18] with limited cytotoxicity
(Fig. S1). Dextran has been widely studied for utilization as
polymeric drug carrier due to its biocompatibility and biodegrad-
ability [19]. In a recent report, Zhang et al. used biocompatible
and non-toxic pH sensitive dextran nanoparticles for drug delivery
application [20]. In this report, we analyzed the effect and stability
of MDR1 siRNA loaded dextran nanoparticles on multidrug
resistant osteosarcoma cell lines.
Materials and Methods
Chemicals
Dextran (Mw,40kDa), stearyl amine (99% pure), cystamine,
pyridine, sodium periodate (NaIO4), sodium cyanoborohydride
(NaCNBH3), potassium sulfate (K2SO4) and azo-bis-isobutyroni-
trile (AIBN) were obtained from Sigma-Aldrich Chemical Co (St.
Louis, MO). Dithiol-modified poly(ethylene glycol) (PEG-(SH)2,
M.W. 2,000) was purchased from SunBio, Inc. (Seoul, South
Korea). Anhydrous lithium chloride (LiCl) was obtained from
Fisher Scientific (Philadelphia, PA). Dehydrated dimethylforma-
mide (DMF) and dimethylsulfoxide (DMSO) with molecular sieves
were obtained from Acros Organics (Parsipanny, NJ). Acryloyl
chloride, pyridine and other reagents and solvents were from
Sigma-Aldrich and were used as received without further
purification.
Synthesis of ABCB1 siRNA
The siRNA sequence targeting ABCB1 (Genbank accession no.
NM_000927) corresponded to coding regions of these genes. Four
target sequences were selected for the ABCB1 gene. Sense
sequences for each siRNA were 59 GAGCUUAACA CC CGA
CUUAUU 39, 59 GAAAGUAUACCUCCAGUUUUU 39, 59
GAC CAUAAAU GUAAG GUUUUU 39, and 59 CCAG-
GUAUGCCUAUUAUUAUU 39. Synthetic siRNA duplexes
were obtained from Dharmacon Inc. (Layfayette, CO). The
siRNAs were dissolved by adding 1 mL of the buffer [100 mmol/L
potassium acetate, 30 mmol/L HEPES-KOH, and 2 mmol/L
magnesium acetate (pH 7.4)] to each tube, and stored at 220uC
until the following transfection experiment. Non-specific siRNA
which has no significant homology to any known gene sequences
from mouse, rat, or human was obtained from Ambion (Austin,
Tx).
Synthesis of lipid-modified dextran polymer
Synthesis of dextran acrylate. The synthesis of dextran
acrylate was based on the procedure of Zhang et al. [21]. Briefly, a
fixed amount of dextran (M.W. ,40kDa, 2 g) was added to a
LiCl/DMF (4% w/v, 50 ml) solvent mixture in a round bottom
flask (200 ml). The temperature of the oil bath was raised from
room temperature to 120uC over a period of 2 h. The resultant
mixture became a homogeneous golden yellow colored solution.
The solution was cooled to room temperature, and pyridine
(500 ml) was added and stirred. The reaction mixture was cooled
to 0uC using ice bath and varying amounts of acryloyl chloride
(1–1.5 molar excess) were added drop wise using an addition
funnel. The reaction was maintained at 0uC until complete
addition of acryloyl chloride was done over a period of 1–2 h. The
reaction was allowed to continue overnight. The dextran-acrylate
obtained was precipitated in excess cold ethanol and washed three
times with absolute ethanol. For confirmation of the formation of
dextran acrylate, a small portion of the acrylate monomer was
polymerized using 0.001% AIBN initiator in DMSO at 60uC for
24 hours, which resulted in formation of the acrylate polymer,
confirming the reaction. Alternately, for lipid modification, the
dextran-acrylate obtained in step 1 was directly used as the
monomer for the next step, in a one-pot synthesis.
Lipid modification of dextran acrylate. A desired amount
(200mg) of dextran acrylate obtained from above step was
dissolved in dry DMF and stirred in a 20ml glass vial with
varying amounts (5–10 mole %) of stearylamine and a catalyst
(0.01 mole % AlCl3). The reaction mixture was heated to 40–50uC
in an oil bath for 24 h. The product obtained (stearylamine -
modified dextran) was precipitated and washed in cold ethanol
several times to purify the product. Finally, the lipid-modified
dextran derivative was dissolved in small amount of deionized
water and lyophilized to yield the pale yellow colored final
product. The fatty amine modification of dextran was confirmed
by 1H NMR spectroscopy (Varian 500MHz NMR spectrometer,
Varian Inc, CA) and the % lipid modification was estimated to be
7 mole% (Fig. 1).
Synthesis of thiolated dextran
Oxidation of dextran. Dextran is an a-D-1, 6-glucose-linked
glucan with side chains 1–3 linked to the backbone units of the
dextran biopolymer. Dextran was selected for the development of
the macrostructure based on its long history of use as plasma
expander and drug delivery platform. The dextran backbone was
oxidized based on the procedure of Martwiset et al. [22]. Briefly, a
desired amount of NaIO4 was dissolved in 60 ml of deionised
water. The solution was added to another solution containing 4 g
of dextran and 30 ml of de-ionised water. The reaction was stirred
in the dark for 2 h at room temperature. At the end of the
reaction, the solution was dialyzed using SpectraporH dialysis
membranes (M.W. cutoff 12–14 kDa, Spectrum Labs, Rancho
Nanoparticles and Osteosarcoma
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Dominguez, CA) against de-ionized water (2L) for 4 days with
several water replacements. A powdery free-flowing sample was
obtained after freeze-drying. Yield: 3.7 g (92.5%).
Thiol modification of dextran. A 500 mg portion of the
oxidized dextran was dissolved in 50 ml pH 5.2 buffer containing
K2SO4 and NaCNBH3. Then 50 mg of cystamine was added and
stirred at 40uC for 4 days. The product was subjected to extensive
dialysis and then lyophilized to yield thiolated-dextran. The
percent thiolation was quantified by Ellman’s reagent [23]. The
concentration of sulfohydryl groups in the purified thiolated
dextran derivate was estimated to be ,14.2 mmole/mg.
Preparation of MDR1 siRNA-containing dextran
nanoparticles
The MDR1 siRNA containing dextran nanoparticles were
prepared in a similar fashion as reported recently for the
preparation of doxorubicin loaded dextran nanosystems [18]. A
stock solution of 5 mg/ml (,2.5 mM) dextran thiol, 5 mg/ml
(,2.5 mM) dextran stearylamine, 5 mg/ml (125 mM) PEG-thiol,
and 2 mM MDR1 siRNA was prepared. For obtaining a 100 nM
siRNA concentration, 120 ml stock solution of MDR1 siRNA was
mixed with 40 ml of dextran-thiol stock solution using a vortex
shaker. It was then incubated for 5 minutes. To this mixture, 40 ml
dextran-stearylamine derivative was then added and incubated for
another 5 mins. Finally 40 ml of PEG-(SH)2 was added and
incubated for another 15 minutes to form the hydrophilic shell of
the nanoparticles. This method of sequential addition was used so
that the siRNA is entrapped in the interpenetrating (IPN) dextran
hydrogel network. Further, a PEG-thiol derivative was used to
provide stealth character to the nanoparticles. The final mixture
was subsequently diluted with the medium and applied at the
designated concentrations. Nanoparticles containing 100 nM
non-specific siRNA was used as negative controls in some
experiments.
Particle size and zeta potential measurements
The particle size and zeta potentials of MDR1 siRNA loaded
nanoparticles were performed with a Brookhaven Zeta PALS
Instrument (Holtsville, NY). For light scattering experiments, the
samples were measured at fixed angle of 90u at 25uC. The
scattering intensity was adjusted in the range of 50–500 kcps by
diluting the samples with deionised water. For zeta potentials,
default parameters of dielectric constant, refractive index, and
viscosity of water were used based on the electrophoretic mobility
of the nanoparticles.
Cell culture and reagents
Dr. Efstathios S. Gonos (National Hellenic research Founda-
tion, Athens, Greece) kindly provided the human osteosarcoma
cell line KHOS and the multidrug resistant MDR1 (P-gp)
expressing cell lines KHOSR2 and U-2OSR2. All cell lines were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 ug/ml streptomycin
(all obtained from invitrogen, Carlsbad, CA). Cells were incubated
at 37uC in 5% CO2-95% air atmosphere and passaged when near
confluent monolayers were achieved using trypsin-EDTA solution.
Resistant cell lines were continuously cultured in 0.1uM
doxorubicin. Doxorubicin was obtained as unused residual clinical
material at the Massachusetts General Hospital. The P-gp1
monoclonal antibody C219 was purchased from Signet (Dedham,
MA). The human b-actin monoclonal antibody and the MTT
reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Figure 1. Characterization of stearylamine-dextran modified nanoparticles. 500 MHz 1H NMR spectra of dextran and dextran conjugated
stearyl amine after purification using D2O as the solvent. The spectra clearly show the additional peaks of the long chain fatty amine at ,1ppm
indicating the successful lipid modification of dextran. The % fat modification was estimated to be 7 mole % of dextran.
doi:10.1371/journal.pone.0010764.g001
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Generation of EGFP expressing cells and transfection by
EGFP siRNA loaded nanoparticles
The Stat3 and enhanced green fluorescent protein (EGFP)
fusion protein expression vector pCORON1000 EGFP-Stat3
(abbreviated as pEGFP-Stat3) was purchased from Amersham
Biosciences (Buckinghamshire, United Kingdom). This pEGFP-
Stat3 vector was generated by fusing Stat3 to the COOH terminus
of EGFP. A hamster kidney cell line (BHK-21) was stably
transfected with pEGFP-Stat3 through selection with G418
(Invitrogen, Carlsbad, CA). EGFP expressing cells were seeded
at a density of 4000 cells per well in 96-well plates with addition of
increased concentration of EGFP siRNA and subsequently
incubated for 48 hr. EGFP siRNA was purchased from Ambion
(Austin, Tx). siPORTTM NeoFXTMTransfection Agent was used
as a positive control (Ambion). Images were acquired by Nikon
Eclipse Ti-U fluorescence microscope (Nikon Corp.) equipped
with a SPOT RT digital camera (Diagnostic Instruments, Inc.,
Sterling Heights, MI).
Western Blot analysis
P-gp1 was analyzed in total cell lysates. Protein lysates from cells
were generated through lysis with 16RIPA Lysis Buffer (Upstate
Biotechnology, Charlottesville, VA). The concentration of the
protein was determined by Protein Assay reagents (Bio-Rad,
Hercules, CA) and a spectrophotometer (Beckman DU-640,
Beckman Instruments, Inc., Columbia, MD). 25 mg of total
protein was processed on Nu-Page 4–12% Bis-Tris Gel (Invitro-
gen) and transferred to a pure nitrocellulose membrane (Bio-Rad
Laboratories, Hecules, CA). Primary antibodies were incubated in
Tris-buffered saline, pH 7.4, with 0.1% Tween 20 overnight at
4uC. Signal was generated through incubation with horseradish
peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules,
CA) incubated in Tris-buffered saline, pH 7.4, with 5% nonfat
milk and 0.1% Tween 20 at 1 : 2000 dilution for 1h at room
temperature. Positive immunoreactions were detected by using
Super Signal HWest Pico Chemiluminescent Substrate (Pierce,
Rockford, IL).
Bands were semi-quantified by reverse image scanning
densitometry with PhotoShop 7.0 (Adobe, San Jose, CA). An
area of the gel image that was devoid of signal was assigned to be
the background value. Then each band of the protein representing
P-gp from KHOSR2 or U2OSR2 treated with various concentra-
tions of MDR1 siRNA nanoparticles was analyzed for density
beyond the background level. To ensure that the loading of the
protein was equal and differences were not being observed because
of one specimen having more protein than another, the band
corresponding to b-actin was determined for each protein. The
density of the protein band was normalized to the b-actin band for
the protein and the ratio of the P-gp was normalized by dividing
by the ratio of the b-actin corresponding to each P-gp.
Duration of MDR1 reversal
For comparison of the duration of MDR1 inhibition by either
MDR1 siRNA with siPORTTM NeoFXTM Transfection Agent or
MDR1 siRNA loaded nanoparticles, 16105 KHOSR2 cells/well
were incubated with each MDR1 siRNA combinations for 5 days.
The expression of P-gp was determined by western blot analysis as
described above.
Drug Efflux Assay
The VybrantTM multi-drug resistance assay kit (Invitrogen/
Molecular Probes) was used to measure the drug efflux properties
of the resistant cell lines. This assay utilizes the fluorogenic dye
calcein acetoxymethyl ester (calcein AM) as a substrate for efflux
activity of P-gp or other membrane pump ABC proteins. Calcein
AM is taken up by cells and hydrolyzed by cytoplasmic esterases
into fluorescent calcein. Calcein is well retained in the cytosol.
However, multidrug resistant cells expressing high levels of P-gp
rapidly extrude non-fluorescent calcein AM from the plasma
membrane, reducing accumulation of fluorescent calcein in the
cytosol. Drug resistant cells (16105) were cultured in 96-well plates
with either increasing concentrations of MDR1 siRNA loaded
nanoparticles or with media alone. After 48 hours, they were
incubated with 0.25 mM calcein AM in 150 ml total volume. Ten
mM Verapamil was used as a positive control. PBS and
nanoparticles loaded with 100 nM nonspecific siRNA were used
as negative controls. After 30 minutes, the cells were washed and
centrifuged twice with 200 ml cold RPMI1640 culture medium,
and cell fluorescence was measured at a wavelength of 490 nm
(A490) on a SPECTRAmaxH Microplate Spectrofluorometer
(Molecular Devices). For visualization of the intracellular retention
of calcein AM, images were acquired by Nikon Eclipse Ti-U
fluorescence microscope (Nikon Corp.) equipped with a SPOT
RT digital camera (Diagnostic Instruments, Inc., Sterling Heights,
MI).
Fluorescence microscopy of cellular doxorubicin uptake
For cellular uptake studies, KHOS and KHOSR2 cells were
seeded at densities of 56105 cells/well in 6 well plates. MDR1
siRNA was applied to a well of KHOSR2 and incubated for 48 h.
Following the incubation, doxorubicin was added to each well and
was incubated for additional 3 hours. After incubation, the cells
were washed, suspended in fresh RPMI 1640, then visualized on a
Nikon Eclipse Ti-U fluorescence microscope (Nikon Corp.)
equipped with a SPOT RT digital camera (Diagnostic Instru-
ments, Inc., Sterling Heights, MI). Fluorescence intensity and
cellular localization was analyzed at a wavelength of 488 nm in
triplicate in random, different fields.
In vitro Cytotoxicity assay
In vitro cytotoxity assays were performed by MTT assay as
previously described. Briefly, 3610 3 cells per well were plated in a
96-well plate during this process. After 48 hours of incubation with
MDR1 siRNA loaded nanocarriers, nonspecific siRNA loaded
nanocarriers or with medium alone, increasing concentrations of
doxorubicin were applied. After culturing for 5 days, 10 ml of
MTT (5 mg/ml in PBS) was added to each well and incubated for
3 hr. After dissolving the resulting formazan product with acid
isopropnol, the absorbance (A490) was read on a SPECTRA max
Microplate Spectrophotometer (Molecular Devices) at a wave-
length of 490 nm. Each experiment was performed in triplicate.
Statistical analysis
Student’s t-test was used to compare the differences between
groups (GraphPad PRISMH 4 software, GraphPad Software, San
Diego, CA). Results are given as mean 6SD and results with
p,0.05 were considered statistically significant.
Results
Lipid-modified dextran nanoparticles for intracellular
MDR1 siRNA delivery
We have recently developed a self assembled nanosystem
based on dextran nanoparticles to stably encapsulate doxoru-
bicin [18]. We used a similar sequential addition method with
some modifications to encapsulate MDR1 siRNA. The seqential
addition method resulted in high encapsulation efficiency of
Nanoparticles and Osteosarcoma
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.95% into the nanoparticles as observed from a FITC-labeled
scrambled sequence siRNA encapslation and release study (data
not shown). The mean particle size of the MDR1 siRNA loaded
nanoparticles as determined by dynamic light scattering (DLS)
measurement was 104.463.7 nm and the zeta potential was
almost neutral (20.1961.13 mV), indicative of the entrapment
of the siRNA within the interpenetrating dextran hydrogel
network. Further, the particles were stable at room temperature
or at 4uC and there was minimal change in the particle size
upon storage (for 1 week at 4uC) as determined by DLS
measurements.
Effect of EGFP siRNA loaded nanoparticle on
BHK-21-EGFP cells
To assess the transfection efficacy of siRNA loaded nanopar-
ticles on cell lines, we first utilized EGFP expressing BHK-21 cells
to test the effects. The EGFP siRNA loaded nanoparticles were
non-toxic at the concentrations utilized in this study (Fig. S2). The
EGFP siRNA was efficiently incorporated into cells and effectively
inhibited the expression of EGFP in a dose dependent manner, but
reached a plateau at approximately 100 nM (Fig. 2).
Stable suppression of P-gp using MDR1siRNA loaded
nanoparticle
Western blotting was performed to estimate the effect of MDR1
siRNA loaded nanoparticle on P-gp expression. P-gp expression
has been previously confirmed in the two drug resistant cell lines
KHOSR2 and U-2OSR2 (data not shown). MDR1 siRNA loaded
nanoparticle inhibited the expression of P-gp at a concentration of
as low as 30 nM (Fig. 3A, B). siRNA transfected with siPORTTM
NeoFXTM Transfection Agent was able to suppress P-gp
expression for 48 hours (Fig. 4A). siRNA loaded nanoparticles
were slower in achieving the suppression of P-gp, but were able to
maintain suppression for 96 hours (Fig. 4B).
MDR1 siRNA loaded nanoparticle inhibits P-gp-mediated
efflux of calcein AM
Reversal of MDR is usually manifested as an increased
intracellular accumulation of chemotherapeutics, which can be
achieved by disturbing P-gp-mediated drug uptake and efflux.
Therefore, the effect of MDR1 siRNA loaded nanoparticles was
examined for the uptake and efflux of a P-gp substrate, calcein
AM, in KHOSR2. Cells treated with MDR1 siRNA were shown to
decrease calcein AM efflux in a dose-dependent manner as
determined by image analysis, and confirmed by microplate
spectrofluorometer analysis (Fig. 5).
Enhancement of intracellular doxorubicin accumulation
with MDR1 siRNA loaded nanoparticle delivery
Using fluorescent microscopy, subcellular distribution of
doxorubicin in KHOS and KHOSR2 was analyzed. After a 3
hour incubation period with free doxorubicin in drug resistant
osteosarcoma cells, the drug was primarily concentrated in the
cytoplasm with a very low level of fluorescence observed in the
nucleus (Fig. 6A). When doxorubicin was administered after
treatment with MDR1 siRNA loaded nanoparticle to drug
Figure 2. Effect of EGFP siRNA loaded nanoparticles on BHK-21-EGFP cells was assessed. EGFP siRNA was efficiently incorporated into
cells and effectively inhibited the expression of EGFP in a dose dependent manner (NP: nanoparticle). siPORTTM NeoFXTM Transfection Agent
(Ambion) was used as a positive control. Nanoparticles loaded with 100 nM non-specific siRNA (c-siRNA) and unloaded nanoparticles were used as
negative controls.
doi:10.1371/journal.pone.0010764.g002
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Figure 3. Western blot assay was performed to assess the effect of MDR1 siRNA loaded nanoparticles on expression of P-gp. The
expression of P-gp was significantly decreased after application of 30 nM MDR1 siRNA loaded nanoparticles for KHOSR2 (A) and 100 nM MDR1 siRNA
loaded nanoparticles for U-2OSR2 (B). P values are shown as follows: *P,0.05.
doi:10.1371/journal.pone.0010764.g003
Nanoparticles and Osteosarcoma
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resistant cell lines, an increase in fluorescence was observed in the
nucleus and cytoplasm (Fig. 6B). This subcellular distribution
mimicked that of the drug sensitive variant when treated with
doxorubicin (Fig. 6C).
In vitro cytotoxicity studies in drug resistant
osteosarcoma cells
The dextran nanoparticles are not cytotoxic by themselves at the
dose used in this study (data not shown). After treatment with MDR1
Figure 4. Western blot assay was performed to assess the duration of MDR1 siRNA loaded nanoparticle. siRNA transfected with
siPORTTM NeoFXTM Transfection Agent was able to suppress P-gp expression for 48 hours (A). Inhibition of P-gp started slower when MDR1 siRNA was
loaded in to nanoparticles, but exhibited longer inhibition compared to MDR1 siRNA transfected with commercially available agent (B). P values are
shown as follows: *P,0.05.
doi:10.1371/journal.pone.0010764.g004
Nanoparticles and Osteosarcoma
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siRNA loaded nanoparticles, we found that doxorubicin showed an
increased amount of anti-proliferative activity in drug resistant
osteosarcoma cell lines in a dose dependent manner (Fig. 7A, B).With
the delivery of nanoparticles loaded with 100 nM MDR1 siRNA,
growth inhibition with doxorubicin was substantially more marked
than with the administration of 100 fold higher amounts of free drugs.
For example, in the KHOSR2 cell line the IC50 of doxorubicin alone
was 10 mM which was reduced to 0.1 mM when the cells were co-
treated with MDR1 siRNA loaded nanoparticles. Likewise, the drug
resistant cell line U-2OSR2 displayed a similar trend; the IC50 for
doxorubicin alone was 6 mM which was reduced to 0.06 mM when
co-treated with the MDR1 siRNA loaded nanoparticles.
Figure 5. Effect of MDR1 siRNA loaded nanoparticle on P-gp – mediated uptake and efflux was analyzed using calcein AM. Cells
treated with MDR1 siRNA were shown to decrease calcein AM efflux in a dose-dependent manner as determined by image analysis, and this was
confirmed by microplate spectrofluorometer analysis. P values are shown as follows: *P,0.05.
doi:10.1371/journal.pone.0010764.g005
Nanoparticles and Osteosarcoma
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Discussion
The primary limitation for the successful treatment of
osteosarcoma is the development of MDR against various
chemotherapeutic agents. Adaptation of cells to drug exposure
involves activation of drug efflux pumps, increased cellular
detoxification, and up-regulation of repair mechanisms, all of
which lead to the development of multidrug resistant character in
cancer cells [24]. Overexpression of the ATP binding cassette
transporters such as ABCB1 (MDR1) has been directly implicated
in resistance to a broad spectrum of chemotherapeutic agents in
vitro including anthracyclines, paclitaxel, and the Vinca alkaloids
[25,26,27]. For several types of cancer, ABCB1 overexpression
may be the predominant factor in limiting the efficacy of
chemotherapeutic agents. Overexpression of the ABCB1 gene
within drug-sensitive cells or mice to produce transgenic animals
confers resistance to the agents described [28,29].
The objective of this study was to investigate the ability of
MDR1 siRNA loaded dextran based nanoparticles to overcome P-
gp mediated drug resistance in osteosarcoma. We developed a
biocompatible and safe nanoparticulate system for the delivery of
MDR1 siRNA, similar to the design reported recently by us for
self-assembled nanosystems for encapsulating doxorubicin [18].
For this purpose, we first incubated the MDR1 siRNA with a
thiol-modified dextran derivative to entrap the siRNA in the
dextran network. This was followed by a sequential addition of a
stearylamine modified dextran derivative (to form an interpene-
trating dextran hydrogel network) and a thiolated PEG derivative
to stabilize the nanoparticles. The combination of several dextran-
lipid derivatives and dextran-thiol polymers and their concentra-
tions were arrived at after several testing of the formulation for
their ability to form stable nanoparticles as assessed by dynamic
light scattering. Also the cytotoxicity testing of various dextran
derivatives were performed to assess their safe use (Fig S1). This
selection approach resulted in the development of a method for
formation of stable nanoparticles with good siRNA loading/
entrapment, supported by the dynamic light scattering data on the
size and charge of the nanoparticles.
We used PEG in our formulation to prepare the nanoparticles
because it is well known that PEGylated liposomes and
Figure 6. Subcellular distribution of doxorubicin in drug sensitive and resistant osteosarcoma cell lines was analyzed under
fluorescence microscope (A-C). A prominent increase in fluorescence was observed in the nucleus when multidrug resistant cells were treated
with doxorubicin after treatment with MDR1 siRNA loaded nanoparticles.
doi:10.1371/journal.pone.0010764.g006
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nanoparticles can impart stealth characteristics to the nanoparti-
cles, increasing the plasma residence time, and protecting the drug
payload from degradation during circulation [30]. PEGlyated
nanoparticles also have the ability to passively target tumor tissues
in vivo by exploiting the inherent abnormalities of the leaky tumor
vasculature [31]. Further, tumor tissues have impaired lymphatic
drainage/recovery system and greatly increased production of a
number of vascular permeability mediators [32]. This phenome-
non is called the enhanced permeability and retention (EPR) effect
[33]. It has been reported that accumulation of nanoparticle
bound drugs are 45–250 times higher in the site of tumors
compared to other vital organs such as the liver, kidney, lung,
spleen, or heart [34].
As a next step for development of nanoparticle delivery system
for overcoming drug resistant osteosarcoma, we tested our
formulation for siRNA silencing effects in vitro. Our results
showed that by treating drug resistant osteosarcoma cell lines with
MDR1 siRNA nanoparticles at concentrations of 30 nM or
higher, the expression of P-gp was effectively suppressed in both
the KHOSR2 and the U-2OSR2 cells. In addition, MDR1 siRNA
loaded nanoparticles were able to suppress the expression of P-gp
for a longer period of time compared to MDR1 siRNA transfected
with commercially available agents (96 hr compared to 48 hr).
Another major obstacle when inhibiting P-gp is that it is not
only present in malignant cells but is also an important constituent
of various normal tissues such as peripheral blood cells and
hemopoietic progenitors found in normal human bone marrow
and the blood brain barrier [35,36,37,38,39]. In these physiolog-
ically normal tissues, P-gp is important in the transport of steroids,
the efflux of toxic molecules, the production of bile, and is an
important component of cellular defense and protection [40,41].
Although P-gp expression in these tissues is relatively low, it may
Figure 7. The effect of doxorubicin alone or nanoparticle loaded with MDR1 siRNA on KHOSR2 and U-2OSR2 was analyzed. Varying
concentrations of doxorubicin was added and cells were cultured for 5 days. Treatment with nanoparticles loaded with MDR1 siRNA showed
increased anti-proliferative activity in both drug resistant osteosarcoma cell lines, KHOSR2 (A) and U-2OSR2 (B), in a dose dependent manner. Growth
inhibition was assessed by MTT as described under Materials and Methods. The experiment was repeated four times in triplicate.
doi:10.1371/journal.pone.0010764.g007
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play an important role in protecting rapidly dividing cells from
toxicity after exposure to anticancer drugs [42]. Consequently,
treatment related morbidity and mortality and increased marrow
toxicity associated with chemotherapeutics and biologicals that
target P-gp limit the clinical application of these agents. To
optimize the application of these agents, it is clear that a delivery
system that achieves higher specificity for target tissue than use of
the agents alone is necessary. Such a system can improve the
therapeutic index of siRNA, increasing the potential for clinical
application.
Nevertheless, measuring a reduction in total cellular P-gp
content does not indicate that the MDR phenotype has been
reversed as only the cell surface-bound portion of P-gp is
responsible for drug efflux [43]. To confirm the reversal of the
MDR phenotype, the VybrantTM multidrug resistance assay was
performed. KHOSR2 cells treated with MDR1 siRNA loaded
nanoparticles showed increased accumulation of the P-gp
substrate calcein-AM by enhancing the uptake and/or decreasing
the efflux of these compounds. There is a possibility that off-target
effects of the mixed siRNAs used in this study might had some
effect on our results, and further investigations using other
sequences of MDR1 siRNA is currently underway to confirm
the functional assay results. The actual accumulation inside cells,
preservation of drug antitumor activity/stability, and subcellular
trafficking are important determinants of the efficacy of an
anticancer agent. For anthracyclines in MDR cells, it has been
reported that in addition to a decrease in drug accumulation, the
intracellular distribution of the drug is rearranged in human
myeloma [44], myeloid [45], lung tumor cells [46], ovarian
carcinoma cells [47], and epidermoid carcinoma cells [48].
Anthracycline fluorescence is found mainly in the nucleus of
sensitive cells and in the cytoplasm of cells with relatively high
levels of resistance [44,45,46,48]. The question then is whether
distribution of doxorubicin will change when drug resistant cells
are treated with MDR1 siRNA loaded nanoparticles. Using
immunofluorescense microscopy, doxorubicin primarily accumu-
lated in the nucleus of drug sensitive cell lines, and in the
cytoplasm of MDR cell lines. When doxorubicin was applied to
MDR osteosarcoma cells treated with MDR1 siRNA loaded
nanoparticles, drug distribution mimicked that of sensitive cells.
The observations indicate that co-treatment with the MDR1
siRNA loaded nanoparticle formulation, by inhibiting P-gp, leads
to higher intracellular doxorubicin concentration which allowed
drugs to accumulate in the nucleus of MDR cells, emulating the
behavior of doxorubicin treatment alone in drug sensitive cells.
Finally, in the treatment of osteosarcoma patients, dose
limitation poses significant problems. After treatment with
nanoparticles loaded with low concentrations of MDR1 siRNA,
drug resistant osteosarcoma cell lines are re-sensitized to
doxorubicin as demonstrated by the results of MTT assay and
by a higher intracellular accumulation of the drug in the nucleus;
demonstrating an uptake and distribution pattern that is
comparable to drug sensitive cells. This evaluation suggests that
low dosages of doxorubicin/MDR1 siRNA therapy show promise
in reducing the systemic lethal side effects which are frequently
encountered in the clinical setting.
In conclusion, this report demonstrates the feasibility of using
MDR1 siRNA loaded dextran nanoparticles to specifically and
effectively modulate MDR. Dextran nanoparticles may be a
successful platform to overcome the current delivery limitation of
siRNA for the treatment of osteosarcoma.
Supporting Information
Figure S1 Cytotoxicity of dextran derivatives vs polyethylenei-
mine(PEI) on NIH3T3 fibroblast (A) and SKOV3 ovarican cancer
(B) cells. Varying concentrations of each nanoparticles were added
and cells were cultured for 5 days. The mixture of dextran
derivatives (thiol+lipid) was found to be almost non-toxic at the
tested concentration relative to PEI. The experiment was repeated
four times in triplicate. (Dex: dextran; DT: dextran thiol; BA:
Butyl amine; HA: hexyl amine; OA: octyl amine; ODA: Octadecyl
amine or stearyl amine; DDA: dodecyl amine).
Found at: doi:10.1371/journal.pone.0010764.s001 (0.07 MB TIF)
Figure S2 The effect of nanoparticles and EGFP siRNA loaded
nanoparticles on BHK-EGFP cells was analyzed. Neither dextran
nanoparticles nor EGFP siRNA loaded nanoparticles were
cytotoxic at a dose utilized in this study. Growth inhibition was
assessed by MTT assay. The experiment was repeated four times
in triplicate.
Found at: doi:10.1371/journal.pone.0010764.s002 (0.06 MB TIF)
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